Bowenoid papulosis is an HPV-related skin condition that causes small, raised bumps in the genital and anal area. It is classified as a form of intraepithelial neoplasia, meaning the affected skin cells show precancerous changes under a microscope, even though the lesions themselves often look harmless. The condition is caused by high-risk strains of the human papillomavirus, most commonly HPV-16, and it tends to affect sexually active adults in their 20s and 30s.
What Bowenoid Papulosis Looks Like
The hallmark of bowenoid papulosis is multiple small, flat-topped papules (firm bumps) that typically measure less than 1 centimeter across. These lesions appear in the anogenital region, often on both sides. In men, the most common sites are the shaft and head of the penis and the scrotum. In women, lesions tend to develop on the vulva, including the clitoris and labia, as well as the area around the vaginal opening.
Color varies depending on skin tone. On lighter skin, the bumps tend to appear pink or slightly red. On darker skin, they are often deeply pigmented, sometimes brown or nearly black. Lesions around the vaginal opening may look whitish rather than pigmented. The papules can merge together into larger patches, and they may have a slightly velvety or rough surface. Most people notice the bumps spreading over weeks to months and seek care because of their appearance rather than pain or itching.
The HPV Connection
Bowenoid papulosis is driven by high-risk types of human papillomavirus, particularly HPV-16, the same strain responsible for most HPV-related cancers. The virus infects skin cells in the genital area and causes them to grow abnormally. Under a microscope, these cells look disordered and show features typically associated with precancer: enlarged, irregular nuclei and increased cell division throughout the full thickness of the skin’s outer layer.
This is what makes bowenoid papulosis unusual. Clinically, the bumps can resemble ordinary genital warts. Histologically (under the microscope), they look almost identical to Bowen disease, which is squamous cell carcinoma in situ, a true precancerous skin condition. The distinction matters because bowenoid papulosis generally carries a better prognosis than Bowen disease, particularly in younger patients. A biopsy is the only reliable way to tell these conditions apart from each other and from common genital warts.
Risk of Becoming Cancer
The precancerous cell changes seen in bowenoid papulosis raise an obvious concern: can it become invasive cancer? The answer is yes, but the risk is relatively low. Estimates for progression from penile or genital intraepithelial neoplasia (the broader category that includes bowenoid papulosis, Bowen disease, and a related condition called erythroplasia of Queyrat) to invasive squamous cell carcinoma range from 10% to 30%. Within that group, bowenoid papulosis sits at the lower end of the risk spectrum.
Certain factors raise the likelihood of progression. Immunosuppression, whether from HIV/AIDS, organ transplant medications, or other causes, significantly increases the chance that abnormal cells will advance. Older age at diagnosis also carries higher risk. In younger, otherwise healthy patients, bowenoid papulosis sometimes resolves on its own, though this is unpredictable and doesn’t eliminate the need for monitoring.
How It Is Diagnosed
Because bowenoid papulosis can closely resemble several other conditions, diagnosis almost always requires a skin biopsy. The list of look-alikes is long: common genital warts (condyloma acuminatum), seborrheic keratoses, lichen planus, psoriasis of the genital area, and other pigmented skin lesions can all produce bumps in similar locations.
Under the microscope, the key finding is full-thickness dysplasia, meaning the abnormal cell changes extend through the entire outer layer of the skin rather than being confined to the bottom portion. This pattern is what places bowenoid papulosis in the same histological category as Bowen disease. HPV testing on the biopsy sample can confirm the presence of a high-risk viral strain and help guide decisions about how aggressively to treat.
Treatment Options
Treatment aims to destroy visible lesions, reduce the risk of progression, and preserve normal function and appearance in a sensitive area. Because bowenoid papulosis involves the genitals, avoiding unnecessary scarring or tissue loss is a priority.
Topical treatments are often the first step. A chemotherapy cream called 5-fluorouracil (5-FU) applied directly to the lesions has long been a popular first-line option. An immune-stimulating cream, imiquimod, is another common choice. It works by activating the body’s own immune response against HPV-infected cells. Used alone, neither cream has an especially high cure rate, but combining them with physical treatments improves outcomes.
Cryotherapy, which involves freezing lesions with liquid nitrogen, is frequently used in combination with topical creams. A typical protocol involves two freeze-thaw cycles per lesion in the office, followed by at-home application of imiquimod several times a week for at least eight weeks, then tapering to a lower frequency for maintenance. Laser therapy, particularly with a carbon dioxide laser, is another effective option. Studies of CO2 laser treatment report complete clearance of lesions, with recurrence rates between 12.5% and 21%.
For lesions that don’t respond to less invasive approaches, surgical options include electrodessication and curettage (burning and scraping the lesion), Mohs surgery (a precise layer-by-layer removal technique), and in some cases of penile involvement, circumcision. These are generally reserved for persistent or recurrent disease.
Recurrence and Long-Term Monitoring
Recurrence is common with bowenoid papulosis regardless of the treatment used. The virus persists in surrounding skin even after visible lesions are cleared, which is why maintenance therapy and regular follow-up are important. Recurrence rates vary by treatment method but generally fall in the range of 12% to 21% for laser-treated lesions, with similar or higher rates for other approaches.
Long-term monitoring typically involves periodic visual examinations of the genital and anal area, with biopsies of any new or changing lesions. For women, regular cervical screening is particularly important because the same HPV strains that cause bowenoid papulosis also cause cervical dysplasia. Sexual partners should be aware of the diagnosis as well, since high-risk HPV is sexually transmitted and partners may benefit from their own screening. HPV vaccination, while it cannot treat an existing infection, can protect against strains a person has not yet been exposed to and is worth discussing for both patients and their partners.